Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Tarsus Pharmaceuticals Inc shares valued at $765,800 were sold by Mottiwala Aziz on Jun 09 ’25. At $43.76 per share, Mottiwala Aziz sold 17,500 shares. The insider’s holdings dropped to 47,557 shares worth approximately $1.95 million following the completion of this transaction.
Also, Mottiwala Aziz purchased 17,500 shares, netting a total of over 782,950 in proceeds.
Before that, Azamian Bobak R. had sold 6,000 shares from its account. In a trade valued at $300,000, the President/CEO and Board Chair traded Tarsus Pharmaceuticals Inc shares for $50.00 each. Upon closing the transaction, the insider’s holdings decreased to 6,000 shares, worth approximately $33.75 million.
As of November 20, 2023, Goldman has initiated its “Neutral” rating for TARS. Earlier on July 18, 2023, William Blair initiated its rating. Their recommendation was “an Outperform” for TARS stock.
Analyzing TARS Stock Performance
On last trading session,, Tarsus Pharmaceuticals Inc [NASDAQ: TARS] plunged -0.02% to $40.95. The stock’s lowest price that day was $39.76, but it reached a high of $41.47 in the same session. During the last five days, there has been a drop of approximately -7.10%. Over the course of the year, Tarsus Pharmaceuticals Inc shares have dropped approximately -26.04%.
Support And Resistance Levels for Tarsus Pharmaceuticals Inc (TARS)
RSI (Relative Strength Index) is 36.92 on the 14-day chart, showing neutral technical sentiment.
Is Tarsus Pharmaceuticals Inc subject to short interest?
Stocks of Tarsus Pharmaceuticals Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.24 million shares to 8.07 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 8.31 million shares. A decline of -2.92% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 11.66 of the overall float, the days-to-cover ratio (short ratio) decline to 11.66.
Which companies own the most shares of Tarsus Pharmaceuticals Inc (TARS)?
In terms of Tarsus Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 67 in the next 12 months, up nearly 63.57% from the previous closing price of $40.96. Analysts anticipate Tarsus Pharmaceuticals Inc stock to reach 84 by 2025, with the lowest price target being 58. In spite of this, 4 analysts ranked Tarsus Pharmaceuticals Inc stock as Buy at the end of 2025.
